Oncothyreon Inc $2.88

up +0.01


29/7/2014 04:00 PM  |  NASDAQ : ONTY  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ONTY Trend Analysis - it has outperformed the S&P 500 by 64%

Partner Headlines

  1. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout ...

    Benzinga
  2. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga
  3. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga
  4. Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ...

    Benzinga
  5. Oncothyreon Says ONT-380 Showed Acceptable Safety Profile

    Benzinga
  6. Five Stocks Making Moves Under $10

    Benzinga
  7. Benzinga's Top Pre-Market Gainers

    Benzinga
  8. US Stock Futures Drop Ahead Of New Home Sales, Durable Goods Data

    Benzinga
  9. Oncothyreon Reports Merck Serono Decision to Continue Development of Tecemotide

    Benzinga
  10. UPDATE: Piper Jaffray Initiates Oncothyreon at Underweight on Pipeline ...

    Benzinga
  11. UPDATE: Wedbush Securities Downgrades Oncothyreon to Neutral, Lowers PT

    Benzinga
  12. Stocks Hitting 52-Week Lows

    Benzinga
  13. Morning Market Losers

    Benzinga
  14. A Peek Into The Market Before The Trading Starts

    Benzinga
  15. Oncothyreon's L-BLP25 Did Not Meet Primary Endpoint in Lung Cancer Trial

    Benzinga
  16. Benzinga's Top Pre-Market Gainers

    Benzinga
  17. UPDATE: Stifel Nicolaus Initiates Oncothyreon at Buy with $10 PT on Stimuvax ...

    Benzinga
  18. Oncothyreon Announces Presentation of PX-866 Clinical Data at American ...

    Benzinga
  19. Stocks Plummet on Global Growth Worries

    MarketIntelligenceCenter
  20. Stocks Slide as Greece Deadline Approaches

    MarketIntelligenceCenter
  21. Oncothyreon Inc. (ONTY) Loses 37% On Wider-Than-Expected Loss

    MarketIntelligenceCenter
  22. Oncothyreon Plunges 40% on Earnings, Date of Final Stimuvax Results

    Benzinga
  23. Cantor Fitzgerald Maintains Buy on Oncothyreon; Phase III Start Trial Continues ...

    Benzinga
  24. Benzinga's Top Pre-Market Losers

    Benzinga
  25. UPDATE: JMP Securities Raises Price Target on Oncothyreon to $14

    Benzinga
  26. HF Manager Shkreli: Betting His Career that Oncothyreon's Stimuvax Drug ...

    Benzinga
  27. Oncothyreon Breeches HOD, Ready to Break Higher

    Benzinga
Trading Center